Antitrust Enforcement In Health Care: A Risky And Evolving Landscape
In the last 18 months, seven companies and four executives in the generic pharmaceuticals manufacturing sector were charged with antitrust violations, amassing penalties of over $426m. And this month, the Department of Justice Antitrust Division brought its first ever criminal charges for a conspiracy to lower wages to workers against the former owner of a physical therapist staffing company. With enforcement efforts ramping up – and COVID-19 adding additional scrutiny – health care companies will need a comprehensive antitrust compliance program to avoid enforcement actions.
You may also be interested in...
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
Yuyao YiJia Daily Chemical told FDA placed all drugs it manufactures on import alert in September because its methods and controls for manufacturing OTC sanitizers and other products do not appear to conform to current drug GMPs.
One of the first US telemed bills out of the gate in 2021 calls for permanently ending limits on CMS telehealth payments.